Ngā hua rapu - Werner Scheithauer

Whakamahine hua
  1. 1
    Clinical trials of agents that reverse multidrug resistance. A literature review

    Clinical trials of agents that reverse multidrug resistance. A literature review mā Markus Raderer, Werner Scheithauer

    I whakaputaina 1993
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Ondansetron for Pruritus Due to Cholestasis

    Ondansetron for Pruritus Due to Cholestasis mā Markus Raderer, Christian A. Müller, Werner Scheithauer

    I whakaputaina 1994
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside mā Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    HER 2/neu protein expression in colorectal cancer

    HER 2/neu protein expression in colorectal cancer mā B. Schuell, Thomas Gruenberger, Werner Scheithauer, Ch. Zielinski, Fritz Wrba

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. mā Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch

    I whakaputaina 1993
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy

    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy mā Markus Borner, Werner Scheithauer, Chris Twelves, Jean A. Maroun, H. Wilke

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid mā Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases mā Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer mā B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial mā Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer

    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer mā Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study

    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study mā Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein

    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein mā R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer mā M. Penz, Gabriela Kornek, Markus Raderer, H. Ulrich-Pur, Wolfgang Fiebiger, A. Lenauer, D. Depisch, G. Krauss, Bruno Schneeweiß, Werner Scheithauer

    I whakaputaina 2001
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... mā Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results mā J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... mā Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma mā H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial mā Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek

    I whakaputaina 2002
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors mā Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent

    I whakaputaina 1994
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: